Interestingly, the anti-tumor effect of anti-GARP:TGF-β1 did not require its binding to FcγRs: tumor rejection was also more frequent (CR: 4/10) when anti-GARP:TGF-β1 FcD was combined with anti-PD-1 FcS. This evidence concerns the gene TGFB1 and neoplasm.